1168 related articles for article (PubMed ID: 30281843)
41. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
42. Moving toward disease modification in polycythemia vera.
Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
[TBL] [Abstract][Full Text] [Related]
43. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
44. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
45. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
46. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
47. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
48. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
49. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
50. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
51. How I treat polycythemia vera.
Passamonti F
Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
[TBL] [Abstract][Full Text] [Related]
52. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Goulart H; Mascarenhas J; Tremblay D
Ann Hematol; 2022 May; 101(5):935-951. PubMed ID: 35344066
[TBL] [Abstract][Full Text] [Related]
53. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
54. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Stein BL; Moliterno AR; Tiu RV
Ann Hematol; 2014 Dec; 93(12):1965-76. PubMed ID: 25270596
[TBL] [Abstract][Full Text] [Related]
55. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
56. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
[TBL] [Abstract][Full Text] [Related]
57. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
58. Polycythaemia vera and essential thrombocythaemia: current treatment strategies.
Penninga EI; Bjerrum OW
Drugs; 2006; 66(17):2173-87. PubMed ID: 17137402
[TBL] [Abstract][Full Text] [Related]
59. Management of polycythemia vera and essential thrombocythemia.
Campbell PJ; Green AR
Hematology Am Soc Hematol Educ Program; 2005; ():201-8. PubMed ID: 16304381
[TBL] [Abstract][Full Text] [Related]
60. Genetic Risk Assessment in Myeloproliferative Neoplasms.
Tefferi A; Vannucchi AM
Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]